nnc0194-0499
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2017 (NCT03015207)
Timeline
Indications
Mechanism of action
FGFR1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nnc0194-0499
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07087795 | Phase 1 | Jul 1, 2025 | Novo Nordisk |
| NCT06409130 | Phase 2 | May 20, 2024 | Novo Nordisk |
| NCT06188026 | Phase 1 | Dec 18, 2023 | Novo Nordisk |
| NCT05917938 | Phase 1 | Jun 29, 2023 | Novo Nordisk |
| NCT05766709 | Phase 1 | Mar 2, 2023 | Novo Nordisk |
| NCT05742919 | Phase 1 | Feb 16, 2023 | Novo Nordisk |
| NCT05727644 | Phase 1 | Feb 15, 2023 | Novo Nordisk |
| NCT05016882 | Phase 2 | Aug 31, 2021 | Novo Nordisk |
| NCT04722653 | Phase 1 | Feb 2, 2021 | Novo Nordisk |
| NCT03479892 | Phase 1 | Mar 13, 2018 | Novo Nordisk |
| NCT03015207 | Phase 1 | Jan 6, 2017 | Novo Nordisk |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novo Nordisk | For profit | 11 | 11 | 2 | 2017 |
1 organizations
Page 1 / 1